However, the limited efficacy against other types of cancers, along with the development of acquired resistance and relapse of Vismodegib and Sonidegib due to mutations in the amino acid of Smo binding site [10], has spurred ongoing efforts to discover alternative Smo inhibitors. The gene discussed is SMO; the disease is cancer.